Brokerages expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report earnings per share of ($0.08) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for ZIOPHARM Oncology’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.08). ZIOPHARM Oncology reported earnings of ($0.12) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The business is expected to report its next quarterly earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.32) per share for the current year, with EPS estimates ranging from ($0.35) to ($0.26). For the next fiscal year, analysts expect that the firm will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.29) to $0.05. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01.
Shares of NASDAQ:ZIOP traded down $0.16 during trading hours on Thursday, hitting $4.25. 1,470,006 shares of the company’s stock traded hands, compared to its average volume of 1,649,403. ZIOPHARM Oncology has a 1 year low of $1.56 and a 1 year high of $5.00. The firm has a market capitalization of $705.98 million, a PE ratio of -8.85 and a beta of 2.64.
Large investors have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in ZIOPHARM Oncology during the first quarter worth approximately $35,000. Amalgamated Bank purchased a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at $37,000. Magnus Financial Group LLC purchased a new position in shares of ZIOPHARM Oncology in the first quarter valued at $39,000. Allred Capital Management LLC purchased a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at $40,000. Finally, SG Americas Securities LLC purchased a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at $46,000. 37.96% of the stock is currently owned by institutional investors and hedge funds.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Featured Story: How is the LIBOR rate calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.